<DOC>
	<DOC>NCT02389816</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of two fixed doses of Lu AA21004 (10 or 20 mg/day) after 8 weeks of treatment in patients with MDD in Japan</brief_summary>
	<brief_title>A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder</brief_title>
	<detailed_description>This is a randomized, double-blind, placebo-controlled, parallel-group, phase III study to assess the efficacy and safety of 8-week treatment of two fixed doses of Lu AA21004 (10 or 20 mg/day) in Japanese subjects with major depressive disorder (MDD).</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>The participant with a primary diagnosis of recurrent MDD according to DSMIVTR criteria (classification code 296.3x). The participant is a man or a woman aged between 20 and 75 years (both inclusive). The reported duration of the participant's current major depressive episode is ≥3 months and ≤12 months. The participant has a MADRS total score ≥26, HAMD17 total score ≥18 and a Clinical Global ImpressionSeverity of Illness (CGIS) score ≥4. The participant has any following current or past history of psychiatric disorder and/or neurological disorder: The participant with any psychiatric disorder other than MDD as defined by the DSMIVTR (To be assessed using MiniInternational Neuropsychiatric Interview (M.I.N.I.)). However, participant with anxiety symptom can be included in the study as long as he/she is not diagnosed with anxiety as defined by the DSMIVTR. The participant with manic, mixed or hypomanic episode, MDD with psychotic features, schizophrenia or any other psychotic disorder (including substancerelated mental disorders, or mental disorders due to a general medical condition) as defined by the DSMIVTR. The participant with any substanceinduced mood disorder (except nicotine and caffeinerelated disorders) as defined by the DSMIVTR. The participant with a positive urine drug screening test result. The participant has current or history of clinically significant neurological disorder (including epilepsy). The participant has neurodegenerative disorder (eg. Alzheimer's disease, Parkinson's disease, multiple sclerosis Huntington's disease). The participant has any DSMIVTR axis II disorder. The participant did not respond to 2 or more adequate antidepressants (treatments of at least 6 weeks duration each at sufficient doses). The participant has received any therapy (e.g. lithium, T3/T4, Lamotrigine, sodium valproate, carbamazepine, additional atypical antipsychotic, or concomitant use of antidepressant, etc.) to enhance the drug effect on current major depressive episode. The participant has shown significant number of major depressive episodes in the past and is suspected of disease other than MDD. The participant has started to experience major depressive episode at a young age and is suspected of disease other than MDD. The participant is at significant risk of suicide or has a score ≥5 on Item 10 (suicidal thoughts) of the MADRS, or has attempted suicide within 6 months prior to the start of Screening period. The participant has experienced/will experience during the study any environmental change (e.g. temporary retirement, returnment, change of residence, etc.) that is determined by the investigator to have the potential to impact on the efficacy evaluation. The participant has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, infectious, neoplastic, skin and subcutaneous tissue disorders, eye disorders or metabolic disturbance.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>